Replies to post #247782 on Biotech Values

[DewDiligence]

Indeed, LLY's Retatrutide has_safety_issues—the 11-14% arrhythmia rate ought to be quite concerning for a drug that will likely be taken chronically (assuming it makes it to market).

As I noted in a prior post, hitting three targets may not be the way to go.